ZAI LAB LIMITED Shareholders' Equity
ZAI LAB LIMITED (ZLAB) had Shareholders' Equity of $607.04 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $607.04M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $661.98M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $715.50M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $759.95M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $607.04M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $661.98M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $715.50M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $759.95M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $791.74M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $810.75M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $840.90M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $667.67M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $704.18M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $762.17M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $796.12M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $880.98M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $932.31M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $1.00B 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $1.05B 10-K · filed 2026-02-26 | |
| 2022-09-30 | $1.11B 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $1.21B 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $1.31B 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $1.38B 10-K · filed 2025-02-27 | |
| 2021-09-30 | $1.59B 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.67B 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $1.01B 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $1.17B 10-K · filed 2024-02-27 | |
| 2020-09-30 | $1.14B 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $465.47M 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $537.59M 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $294.66M 10-K · filed 2023-03-01 | |
| 2019-09-30 | $337.11M 6-K · filed 2020-01-21 | |
| 2019-06-30 | $393.33M 6-K · filed 2020-09-11 | |
| 2018-12-31 | $251.08M 10-K · filed 2022-03-01 | $251.08M 20-F · filed 2019-03-29 |
| 2018-09-30 | $309.06M 6-K · filed 2020-01-21 | |
| 2017-12-31 | $235.17M 10-K · filed 2021-03-01 | $235.17M 20-F · filed 2018-04-30 |
| 2016-12-31 | -$51.55M 20-F · filed 2020-04-29 | -$51.55M 20-F · filed 2018-04-30 |
| 2015-12-31 | -$18.37M 20-F · filed 2019-03-29 | |
| 2014-12-31 | -$2.95M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |